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Overactive bladder syndrome (OAB) refers to individuals with the following symptoms: urinary urgency, increased urinary
frequency, and urge incontinence. These symptoms are not life threatening but can cause embarrassment and signiﬁcantly
impact quality of life. There are numerous treatment options for OAB, including behavioral therapy, traditional pharmacological
therapy or a combination of the two. These options are considered the mainstay of treatment for OAB. We carried out a
comprehensive systematic review of the available literature on the eﬀectiveness of behavioral intervention, anticholinergic drugs,
and their combination in the management of adults with overactive bladder, with emphasis on results from clinical trials
and primary literature. Each treatment intervention is eﬃcacious, and the choice should be based on the patient’s severity of
symptoms, tolerability, compliance and satisfaction with the treatment. Based on available literature, management of OAB using
a combination of behavioral therapy and drug intervention is the most eﬃcacious in terms of patient satisfaction, perceived
improvement, and reduction of bladder symptoms. It is also the most practical and cost eﬀective for optimal management of
patients with OAB. Pharmacological treatment, in addition to behavioral therapy, remains important in the management of adults
with OAB syndrome.
Copyright © 2009 Khanh Tran et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
O A Bi sac o m m o nu r i n a r yd y s f u n c t i o ni nb o t hm e n
and women, symptoms of which include urinary urgency,
urinary frequency, nocturia, and urinary urge incontinence.
OAB is estimated to occur in 33 million Americans or
approximately 16.5% of the population [1–4]. In the long-
term care setting, it is estimated that as many as half
of all female residents suﬀer from incontinence [3, 4].
OAB is a serious medical and ﬁnancial concern for several
reasons. OAB is associated with medical and quality of life
consequences that further compromise the health and well
being of institutionalized and community-dwelling patients.
Speciﬁcally, urinary incontinence (UI) has been associated
with an increased risk of urinary tract infections, pressure
ulcers, falls and fractures, which may severely compromise
patient function and overall health [4–6]. Incontinence also
consumes medical resources, staﬀ, and provider time, which
drives up the cost of care [6].
UI has been estimated to aﬀect 20–33% of adults and
greater percentages of the elderly [1–4]. UI is approximately
twice as common among women than among men [5,
6]. Based on recent epidemiological studies, the overall
prevalence of UI in women is 16.9%, which translates into
an estimated 17.5 million women in the United States
who suﬀer from this condition [7]. Prevalence increases
with age, from 4.8% in women under the age of 25 to
30.9% in those over the age of 65 [7]. Elderly women that
are institutionalized have a signiﬁcantly higher prevalence
of UI than those living at home, which is one of the
contributing factors to institutionalization [1, 4]. Despite the
high estimate of prevalence, however, it is believed that as
many as 50% of all cases of UI may not be reported, and that
individuals with UI do not always seek medical help [8–10].2 Advances in Urology
UI has a substantial impact on physical and mental
quality of life. The estimated total economic cost for UI
was $19.5 billion in 2000 [5]. When indirect costs such
as lost wages and productivity are included, the annual
cost of incontinence increases to more than $26 billion,
with institutional care accounting for more than 23% ($8.4
billion) [11]. In addition, the need for eﬀective management
strategiesincreasesproportionallyasthepopulationagesand
the proportion of elderly individuals aged 65 years and older
increases.
The main symptom of OAB is urgency, or a sudden and
compelling desire to pass urine which is diﬃcult to defer
[12].Sometimes thereisaninvoluntary leakageofurine with
the feeling of urgency, which is called urge incontinence. The
main complaints among individuals with OAB are the need
to void too often during the day, and waking once or more
per night to void [13]. In clinical practice, the need to void
more than eight times during the day is considered daytime
frequency,whilewakingfromsleepmorethanoncepernight
to void is considered nocturia.
Urgency and urge incontinence usually result from an
involuntary increase in bladder pressure due to bladder
smooth muscle over-activity during the ﬁlling phase of the
micturition cycle. The pathophysiology of OAB remains
unclear,buttherearetwowidelyacceptedexplanations.First,
partial denervation of the detrusor muscle is believed to
increase excitability secondary to changes in central nervous
system (CNS) pathways that inhibit bladder activity [14].
Second, increased sensitivity of the sensory nerve endings in
the bladder results in increased excitability of the detrusor
muscle [14]. In either case, increased cholinergic stimulation
of the detrusor occurs via postsynaptic muscarinic receptors
[12].
The bladder contains both M2 and M3 subtypes of the
muscarinic receptor. Even though the M2 s u b t y p ei sm o r e
abundant, it is the M3 subtype that is mainly responsible
for bladder contraction [15]. As a result, pharmacotherapy
focuses mainly on the use of drugs with anticholinergic
properties to block the parasympathetic acetycholine path-
way and reduce the intensity of detrusor muscle contraction
[16, 17]. By partially blocking the binding of acetycholine to
detrusor muscarinic receptors, anticholinergic agents reduce
the level of stimulation via parasympathetic neural impulses.
Through this mechanism, anticholinergic therapy increases
bladder capacity and delays the initial urge to void, thereby
reducing the symptoms of OAB [12]. However, none of
the current anticholinergic medications act speciﬁcally on
muscarinic receptors in the bladder; they also act in other
parts of the body, where they cause dry mouth, constipation,
nausea, and other adverse eﬀects.
Since OAB is a chronic condition, the goal in treatment
is to reduce long-term health care costs, and increase
quality of life (QOL) and patient satisfaction. In addition
to antimuscarinic treatments, other current treatments for
UI include behavioral modiﬁcation, such as bladder train-
ing, ﬂuid manipulation, scheduled toileting, pelvic muscle
exercises, and surgical interventions. Often, pharmacological
treatmentandbehavioralmodiﬁcationarecombined[11,18,
19].
Behavioral therapies are currently recommended as a
ﬁrst line therapy in the treatment of UI [20, 21]. Behav-
ioral interventions are usually relatively inexpensive and
easy to implement, but their eﬀectiveness depends chieﬂy
on patient motivation and compliance [22]. Thus, this
type of treatment requires a high level of motivation and
encouragement. The advantages of behavioral methods are
improved central control of bladder function, avoidance of
the mortality and morbidity of surgery, and no adverse drug
reactions.
When nonpharmacological interventions have failed,
drug therapy is commonly employed [10]. Drug treatment
continues to play an important role in the management of
women with UI, although many of the agents used have not
been subjected to controlled clinical trials [23]. Based on a
review of clinical studies reported in the literature, it is clear
that there is no ideal drug, and there is a critical need for
improved pharmacotherapy [24]. Current pharmacological
approaches to improving the treatment of UI include
delayed release formulations of existing oral agents, new
pharmaceutical agents with greater speciﬁcity/selectivity,
and alternative routes of administration. New generation
pharmacological treatments, such as extended release (ER)
tolterodine and transdermal oxybutynin, provide better
or comparable eﬃcacy with fewer adverse drug events
[25–27].
2. Behavioral Therapies for Overactive
Bladder and UI
As mentioned, behavioral therapies are considered the
mainstay of treatment for urinary incontinence because
they are noninvasive and can be initiated at the primary
care level. However, the role that behavioral therapies play
in the treatment of OAB has not been well addressed in
the literature. Behavioral interventions include pelvic ﬂoor
muscle training (PFMT), bladder training, and lifestyle
modiﬁcation. Lifestyle modiﬁcations for the management of
OAB include smoking cessation, caﬀeine reduction, reduced
alcohol consumption, weight loss, and limiting ﬂuid intake.
Several clinical trials have shown evidence of a relationship
between obesity and OAB, suggesting that weight loss may
signiﬁcantly reduce episodes of urge incontinence [28–31].
There appears to be a dose-dependent relationship
between caﬀeine and OAB. Patients with high caﬀeine intake
(>400mg/day) were 2.4 times more likely to experience
detrusor overactivity [32]. Limiting ﬂuid intake may also
reduce frequency/urgency in OAB and improve patient
quality of life [31, 33].
PFMT is most commonly used as a treatment for stress
UI. The impact of PFMT appears to be multifactorial. In
addition to the reﬂex inhibition of involuntary detrusor
contraction, PFMT may provide the physical ability to
voluntary contract the external sphincter and regain bladder
control [34, 35]. Evidence to support the eﬃcacy of PFMT
for OAB is growing [36]. Patients with detrusor over activity
who completed a PFMT program experienced a signiﬁcant
andclinicallyrelevantreductionindailyUIepisodes[35,36].
There was also a signiﬁcant decrease in urge score, deﬁned asAdvances in Urology 3
the frequency of leakage (0 = never to 4 = always) during 9
activities that can trigger urge incontinence.
Bladder training (BT) involves a systematic voiding
regimen to lengthen the interval between voids until an
acceptablepatternhasbeenrestored.Bladderdiariesareused
to establish maximum baseline voiding intervals, which are
progressively increased by 15 to 30 minutes as tolerated.
BT has been used for patients with stress incontinence,
detrusor overactivity, or mixed incontinence, and clinical
studieshavedemonstratedtheeﬀectivenessofBTinrelieving
the symptoms of UI [37, 38]. BT resulted in a signiﬁcant
reduction in UI episodes, including a signiﬁcant decrease in
volume of urine lost per UI episode. Despite this evidence
of eﬃcacy, however, the mechanism of BT’s impact remains
unclear, and there is little support for the common assertion
that BT increases bladder capacity. McClish and coworkers
reported a signiﬁcant reduction in UI but no signiﬁcant
change in urodynamic parameters after 6 weeks of BT, while
Else and colleagues found a signiﬁcant increase in capacity
at ﬁrst sensation to void but not in maximum cystometric
capacity [39, 40]. Regardless of mechanism, these studies
demonstrate the eﬀectiveness of BT in reducing UI.
Although behavioral modiﬁcation has proven to be
eﬀective in reducing the symptoms of UI and OAB, it is not
considered a cure. In addition, there have been no head-
to-head trials of diﬀerent behavioral interventions which
would support one type over another. Increasingly, the
emphasis in treatment of OAB is on combined behavioral
and pharmacologic therapy.
3. Pharmacotherapy for OAB and UI
Anticholinergic drugs have been available for the treatment
of OAB for years and their use is widespread in clinical
practice. The number of anticholinergics on the market
is increasing, and their eﬀectiveness has been assessed in
many studies [41–45]. There are questions regarding the
role of anticholinergics in diﬀerent patient groups such as
the elderly, men, women, and patients with comorbidities,
as well as the best route of administration. Despite these
uncertainties, anticholinergics are increasingly being used
in primary and secondary settings, particularly for the
treatment of urge incontinence [46].
The International Consultation on Incontinence rec-
ommends anticholinergics as a ﬁrst line pharmacotherapy
in urge incontinence for men, women, the elderly, and
patients with neurogenic detrusor overactivity. The main
disadvantage to the use of this class of drug is the side eﬀect
proﬁle. Newer generation anticholinergic medications have
fewer side eﬀects as compared to the older generations, but
drymouthisstillacommonadverseeﬀectreportedinalmost
one third of patients receiving these drugs [47]. Also, there
are few studies that report the long-term eﬀectiveness of
these drugs [17].
3.1. Oxybutynin. Oxybutynin is an anticholinergic agent
that has antimuscarinic, antispasmodic, and potential local
anesthetic eﬀects [48, 49]. It has been in widespread clinical
use since 1975 and has been the most extensively studied in
this class of drugs by clinicians. It is available in immediate-
release (Ditropan), extended-release (Ditropan XL), and
transdermal(Oxytrol)forms.Oxybutyninhasbeenshownto
have a high aﬃnity for muscarinic receptors in the bladder,
with a higher aﬃnity for M1 and M3 receptors than M2
[50, 51]. The eﬀectiveness of diﬀerent forms of oxybutynin
in the management of patients with detrusor overactivity is
well documented.
A 2007 study by Stohrere and colleagues found that
immediate release (IR) oxybutynin increased maximum
cytometric capacity from 164 to 298mL and decreased
maximum detrusor pressure from 68.6 to 43.1cm H2Oi n
patients with detrusor overactivity [52]. A trial of extended-
releaseoxybutynin(oxybutyninXL)showedthatcystometric
bladder capacity increased from 274 to 380mL and inconti-
nence episodes dropped from 13 to 6 per week, even though
postvoid residual urine increased in patients treated with
oxybutynin XL [53].
Oxybutynin XL has a less severe dry mouth side eﬀect
than oxybutynin IR and is more commonly used in practice
[53]. In one study, the incidence of moderate to severe dry
mouth in patients on oxybutynin XL was 23%, with only
1.6%ofpatientsdiscontinuingthemedicationduetoadverse
eﬀects [54]. A follow-up study that evaluated oxybutynin XL
in patients with comorbidities (spinal cord injury, multiple
sclerosis, and Parkinsonism) conﬁrmed the improvement in
urodynamicparameters[55].Thelatterstudyconcludedthat
the administration of up to 30mg/day of oxybutynin XL was
botheﬃcaciousandsafeinthesepopulations.Recentlyitwas
demonstrated that the use of oxybutynin XL in the elderly
may impair recent memory [56].
I no r d e rt om a x i m i z ee ﬃcacy and minimize adverse
eﬀects, an oxybutynin transdermal delivery system
(oxybutynin-TDS) was recently developed and compared
with oxybutynin XL. Oxybutynin—TDS increased cystomic
capacity from 247mL to 395mL, increased reﬂex volume
from 190mL to 249mL, and decreased maximum detrusor
pressure from 61.2 to 37.8cm H2O[ 57]. A maximum dose
of 11.7mg per day was found to be well tolerated by patients
while improving continence. In a related study comparing
oxybutynin-TDS to tolterodine, the most common side
eﬀect was application site reaction (14%), and the incidence
of dry mouth was reduced to 4.1% as compared to the
tolterodine treatment group (7.3%) [58].
3.2. Tolterodine. Tolterodine is a competitive muscarinic
receptor antagonist with relative functional selectivity for
bladder muscarinic receptors [59]. While the drug shows
no speciﬁcity for receptor subtypes, it does appear to target
the bladder over the salivary gland [60]. Tolterodine is
available in immediate- and extended- release forms, and
both formulations showed good eﬃcacy for symptoms of
OAB in a large study population [61]. However, extended-
release is preferred by both clinicians and patients due
to a less severe side eﬀect proﬁle [62]. In a randomized
controlled study of tolterodine XL 4mg/day in patients with
urgeincontinenceandurinaryfrequency,nodiﬀerenceswere
foundintermsofeﬃcacy,tolerability,orsafetybetweenolder
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A recent trial comparing tolterodine XL to tolterodine IR
and placebo found tolterodine XL to be signiﬁcantly more
eﬀective [63]. In addition to increased eﬃcacy, tolterodine
XL has been shown to have better tolerability. In a double-
blind, multicenter, randomized placebo controlled trial,
tolterodine XL was found to be 18% more eﬀective in
reducing episodes of urge incontinence, with a 23% lower
incidence of dry mouth [64]. The eﬃcacy of tolterodine XL
was conﬁrmed in several clinical trials, including the OPERA
(Overactive bladder: Performance of Extended Release
Agents), OBJECT (Overactive Bladder: Judging Eﬀective
ControlandTreatment),andACET(AntimuscarinicClinical
Eﬀectiveness Trial) studies [65–67]. The safety of tolterodine
hasalsobeenconﬁrmed,andattherecommendeddailydose,
the incidence of adverse events was no diﬀerent than placebo
[68].
In a comparison of the safety and eﬃcacy of tolterodine
versus oxybutynin, clinical eﬃcacy was similar for both
drugs; however oxybutynin had higher withdrawal rates and
a higher incidence of dry mouth [45, 69].
3.3. Trospium Chloride. Trospium is a smooth muscle relax-
ant that is nonselective for muscarinic receptor subtypes
[70]. It is a quaternary ammonium compound that was
recently approved by the US Food and Drug Administration
(FDA) for the treatment of OAB [71]. Trospium was initially
provided as a single 20mg dose for twice daily use; it
has more recently been approved in a 60mg once daily
formulation. In multiple eﬃcacy trials in OAB patients,
trospium produced signiﬁcant improvements in maximum
detrusor pressure, maximum cystometric capacity, and blad-
der volume at ﬁrst involuntary contraction [72–75]. In a
study testing double daily dosages of trospium chloride
(90mg) in a mixed incontinence patient population that
did not respond well with a standard dose, treatment with
a double dose yielded improvements in reﬂex volume,
cystometric capacity, and detrusor pressure as compared
with a standard dose (45mg) [73]. When an even higher
dosage (90mg/day) of trospium chloride was tested, it
was reported that patients who were not responsive to
the standard dose (45mg) could be safely treated with up
to three times the dose of trospium/day [76]. Similar to
solifenacin (see below), trospium chloride may have a lower
risk of CNS side eﬀects because of its lower predilection
to cross the blood-brain barrier [77]. It also has the added
beneﬁt of being metabolized by the kidneys rather than the
cytochrome P450 system, thereby having fewer interactions
with other medications [77]. Thus, this therapy may be
beneﬁcial for patients who are elderly and/or receiving
multiple medications.
Trospium has been compared to oxybutynin in a ran-
domized, multicenter trial [78]. The trial found that with
both agents, there was a signiﬁcant increase in bladder
capacity, a decrease in maximum voiding detrusor pressure
and a signiﬁcant increase in compliance as compared to
placebo, although there were no statistically signiﬁcant
diﬀerencesbetweenthetwotreatmentgroups[78].However,
patients taking trospium had a lower incidence of dry
mouth and were less likely to withdraw as compared to the
oxybutynin group [78].
3.4. Solifenacin. Solifenacin is an antimuscarinic agent and a
potent M3 receptor antagonist that has selectivity for the M3
over the M2 receptor [79]. It also has much higher potency
againsttheM3 receptorinsmoothmusclethanitdoesagainst
theM3 receptorinthesalivarygland[79].Solifenacineﬃcacy
has been proven in multiple trials in OAB patients [80–82].
For instance, phase III studies with solifenacin (5 and 10mg)
consistently showed it to be more eﬀective than placebo
for all OAB variables measured [80]. A recent SUNRISE
studyshowedthatsolifenacinwassigniﬁcantlymoreeﬀective
than placebo in reducing the mean number of episodes of
severe urgency with or without incontinence per 24 hours,
improved urgency as early as day 3 of treatment, and was
well tolerated [83]. Importantly, in contrast to oxybutynin,
it is postulated that solifenacin is very unlikely to cross the
blood brain barrier due to its biochemistry, and no cognitive
impairmentassociatedwiththisdrughasbeenreported[84].
In a direct comparison between solifenacin in 5 and
10mg doses and tolterodine XL in a randomized, double-
blind trial, solifenacin was at least as eﬀective as tolterodine
XLinreducingmicturitionfrequency,anditwassigniﬁcantly
more eﬀective than tolterodine XL in improving most other
OAB variables [81]. In a meta-analysis of seven placebo-
controlled OAB studies, the mean and median reductions
in the number of urgency episodes with solifenacin were
greater than with several other agents such as oxybutynin,
tolterodine, trospium, and darifenacin [85]. These studies
suggest that solifenacin is an eﬀective treatment for OAB
with the most commonly reported adverse events being dry
mouth, constipation, and blurred vision.
3.5. Darifenacin. Darifenacin is a highly selective M3 recep-
tor antagonist that was approved in 2004 for the treatment
of OAB. It has a ﬁvefold higher aﬃnity for the M3
receptor relative to the M1 receptor [79]. This M3-selective
receptor antagonist is potentially more bladder-speciﬁc,
with a reduced tendency for anticholinergic side eﬀects
[86]. Darifenacin is available in 7.5mg/day and 15mg/day
formulations. The drug is associated with relatively high
rates of constipation (14.4% for darifenacin 7.5mg daily)
[87]. The eﬃcacy of darifenacin has been investigated in
several multicenter studies [88–91]. Darifenacin was signif-
icantly superior to placebo for improvements in micturition
frequency, bladder capacity, frequency of urgency, severity
of urgency, and number of incontinence episodes leading
to a change in clothing or pads. In a comparison of
darifenacin to oxybutynin, both drugs had similar eﬃcacy;
however, darifenacin had a less severe side eﬀect proﬁle than
oxybutynin [92].
The most common adverse events associated with dar-
ifenacin are mild to moderate dry mouth and constipation,
with a CNS and cardiac safety proﬁle. Darifenacin has also
been tested in patients who expressed dissatisfaction with
prior OAB treatment with oxybutynin ER or tolterodine ER
due to insuﬃcient eﬃcacy, tolerability problems, or both.Advances in Urology 5
Table 1: Impact of various interventions in OAB patients.
Intervention Outcome References
Weight loss Obesity associated with OAB, moderate weight loss
associated with improvement in urge UI
[28–31]
Caﬀeine restriction
Relationship between caﬀeine intake and OAB in
men/women not signiﬁcant: impact of caﬀeine on OAB
may be dose dependent
[32]
Fluid restriction Limiting ﬂuid intake may reduce frequency/urgency in
OAB, improve quality of life
[31, 33]
Bladder training
Used for patients with stress incontinence, detrusor
overactivity, or mixed incontinence: lengthen the
interval between voids, signiﬁcant reduction in UI
episodes in 3-day bladder diaries, and signiﬁcant
decrease in volume of urine lost
[37, 38]
Pelvic ﬂoor muscle training
Common treatment of stress UI: signiﬁcant reduction
of daily UI frequency, night time UI frequency, and
frequency of leakage
[35, 36]
Oxybutynin (immediate release,
extended release, transdermal)
Increased maximum cytometric capacity and decreased
maximum detrusor pressure in patients with detrusor
overactivity
[52–54, 57]
Tolterodine (immediate,
extended-release forms)
Increased maximum detrusor pressure, reﬂex volume,
and cystometric capacity but lower withdrawal rates
and less incidence of dry mouth compared to
oxybutynin
[65–69]
Trospium chloride
Produced signiﬁcant improvement in maximum
detrusor pressure, maximum cystometric capacity, and
bladder volume; beneﬁcial for patients who are elderly
and/or receiving multiple medications due to its lower
predilection to cross the blood-brain barrier
[72–75, 77]
Solifenacin
Eﬀective in reducing micturition frequency, reducing
the mean number of episodes of severe urgency with or
without incontinence per 24 hours and improving
urgency at day 3 of treatment; improves most other
OAB variables
[80–84]
Darifenacin
Signiﬁcantly superior to placebo for improving
micturition frequency, bladder capacity, frequency of
urgency, severity of urgency, and number of
incontinence episodes leading to a change in clothing
or pads; can be used for elderly population due to lower
nervous system eﬀects
[87–90, 93]
Behavior and drug therapies
Combination therapy produced added beneﬁt in terms
of patient satisfaction, perceived improvement and
reduction of bladder symptoms; anticholinergic may
work synergistically with behavioral intervention
because of the diﬀerent mechanisms involved
[8, 20, 21, 94–98]6 Advances in Urology
The results of this trial showed signiﬁcant improvements in
OAB symptoms with darifenacin [86]. Long-term studies
have shown that there are high levels of persistence with
darifenacin therapy and well-maintained treatment beneﬁts
(over 2 years in duration) [93, 99]. Darifenacin minimizes
the risk of functional side eﬀects due to blockade of
other muscarinic subtypes, such as M1-mediated cognitive
impairment[94].Thisaspectofdarifenacintherapybecomes
important in the treatment of elderly populations who
may be more susceptible to cognitive impairment and CNS
eﬀects. This patient population is at an increased risk of
advanced age conditions such as diabetes, Alzheimer’s, or
multiple sclerosis. One analysis by Foote in patients aged 65
years or more found that darifenacin had a low incidence of
nervous system eﬀects (somnolence, dizziness), but showed
a signiﬁcant improvement in all OAB scores.
4. Behavioral and Drug Therapy for OAB
A combination of anticholinergic agents and behavioral
interventions is a safe and eﬀective ﬁrst-line treatment for
OAB [8, 20, 21, 95]. Most patients do not achieve complete
continence with either therapy alone. In addition, long-
term medication adherence can be diﬃcult due to side
eﬀect proﬁles. Adding behavioral training to pharmacologic
treatment is an appealing approach to improving outcomes
and to possibly permitting discontinuation of drug therapy.
Moreover, anticholinergics may work synergistically with
behavioral intervention, due to the diﬀerent mechanisms
involved [96]. Many trials have shown the synergistic eﬀect
of these two interventions (Table 1).
The Mattiasson trial showed that a combination of
tolterodine and BT signiﬁcantly reduced void frequency and
increased volume per void as compared to tolterodine alone
[97]. Furthermore, 76% of the patients on tolterodine and
BT reported an improvement in their bladder symptoms
relative to baseline as compared with 71% in the tolterodine
group [97]. This ﬁnding is consistent with a previous
trial showing that BT signiﬁcantly increases the eﬃcacy of
tolterodine for reducing voiding frequency and increasing
volume voided [98].
Clinical data has also shown that combination therapy
is associated with signiﬁcantly fewer incontinent episodes,
better quality of life, and greater treatment satisfaction
as compared to nonpharmacologic intervention alone or
drug treatment alone [100]. However, the eﬀects of each of
the 3 interventions were similar 3 months after treatment,
suggesting that the nature of the treatment may not be as
important as having a structured intervention program that
includes education, counseling, and frequent monitoring of
the treatment [100].
5. Summary and Conclusions
The choice of therapy for treating patients with OAB will
be based on many factors, including prognosis of under-
lying disease, mental status, age, education, motivation,
and mobility, and should be tailored to the individual.
Aconservativemanagementregimewouldbeginwithsimple
therapy(behavioralintervention) beforeproceeding tophar-
macologicaltreatment.Duetothecomplexitiesofthedisease
andindividualvariability,nosingletreatmentforOABexists.
Rather, several treatments are typically begun and modiﬁed
in order to meet the patient’s desired therapeutic goal. The
main goal in treating OAB is the preservation of upper
urinary tract function and improvement of the patient’s
troubling urinary symptoms.
The prevalence of OAB is expected to increase in the
future with the increasing number of elderly individuals in
the population, emphasizing the need for methods to suc-
cessfully manage OAB. Given the eﬀectiveness of behavioral
therapy, such as the absence of side eﬀects, low cost, and ease
of implementation in the outpatient setting, this approach
is generally recommend as the ﬁrst choice for OAB in the
elderly.
The eﬀectiveness of drug therapy and behavioral inter-
ventions for reducing urinary incontinence is well estab-
lished [96–98, 100, 101] .T h e r ei ss t r o n ge v i d e n c et h a ta
combination of approaches is useful in helping patients
with OAB reduce incontinence episodes in certain settings.
However, although combination therapy may be beneﬁcial
forreducingincontinencefrequencyduringactivetreatment,
asteppedapproach,inwhichasingleinterventionisinitiated
ﬁrst and then a second therapy is added for patients who do
not achieve a satisfactory outcome, may be more practical
and cost eﬀective for optimal management of patients with
OAB.
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